Intratracheal Administration of siRNA Triggers mRNA Silencing in the Lung to Modulate T Cell Immune Response and Lung Inflammation

Clinical application of siRNA-based therapeutics outside of the liver has been hindered by the inefficient delivery of siRNA effector molecules into extra-hepatic organs and cells of interest. To understand the parameters that enable RNAi activity in vivo, it is necessary to develop a systematic app...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Bruce, Cash-Mason, Tanesha, Wang, Yi, Seitzer, Jessica, Burchard, Julja, Brown, Duncan, Dudkin, Vadim, Davide, Joseph, Jadhav, Vasant, Sepp-Lorenzino, Laura, Cejas, Pedro J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426712/
https://www.ncbi.nlm.nih.gov/pubmed/30901578
http://dx.doi.org/10.1016/j.omtn.2019.02.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426712/
https://www.ncbi.nlm.nih.gov/pubmed/30901578
http://dx.doi.org/10.1016/j.omtn.2019.02.013

Ejemplares similares